Avenue Therapeutics, Inc. (ATXI): Price and Financial Metrics


Avenue Therapeutics, Inc. (ATXI)

Today's Latest Price: $10.92 USD

0.01 (0.09%)

Updated Sep 25 4:00pm

Add ATXI to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 233 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

ATXI Daily Price Range
ATXI 52-Week Price Range

ATXI Stock Price Chart Technical Analysis Charts


ATXI Price/Volume Stats

Current price $10.92 52-week high $12.34
Prev. close $10.91 52-week low $4.96
Day low $10.80 Volume 37,691
Day high $11.16 Avg. volume 56,045
50-day MA $11.00 Dividend yield N/A
200-day MA $9.77 Market Cap 182.40M

Avenue Therapeutics, Inc. (ATXI) Company Bio


Avenue Therapeutics, Inc., a specialty pharmaceutical company, acquires, licenses, develops, and commercializes an intravenous formulation of tramadol HCI principally for use in the acute/intensive care hospital setting. Its product candidate is IV Tramadol for the treatment of post-operative pain. The company was founded in 2015 and is based in New York, New York.


ATXI Latest News Stream


Event/Time News Detail
Loading, please wait...

ATXI Latest Social Stream


Loading social stream, please wait...

View Full ATXI Social Stream

Latest ATXI News From Around the Web

Below are the latest news stories about Avenue Therapeutics Inc that investors may wish to consider to help them evaluate ATXI as an investment opportunity.

Avenue Therapeutics Announces Publication of a Review of IV Tramadol

NEW YORK, Sept. 09, 2020 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced that a publication entitled “IV tramadol: A novel option for US patients with acute pain—A review of its pharmacokinetics, abuse potential and clinical safety record” has been published in the peer-reviewed journal, Journal of Opioid Management, and can be accessed here. This paper provides a review of the pharmacokinetics (“PK”) of the IV tramadol dosing regimen intended for the U.S., its abuse potential as documented in the literature, its safety record in clinical practice outside the U.S. and discusses how IV tramadol may become a useful option for patients with acute pain in the U....

Yahoo | September 9, 2020

Avenue Therapeutics, Inc. (ATXI) Dips More Than Broader Markets: What You Should Know

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.30, moving -1.9% from the previous trading session.

Yahoo | July 28, 2020

Avenue Therapeutics, Inc. (ATXI) Stock Sinks As Market Gains: What You Should Know

Avenue Therapeutics, Inc. (ATXI) closed the most recent trading day at $10.40, moving -1.61% from the previous trading session.

Yahoo | July 22, 2020

Avenue Therapeutics Announces Publication of Phase 3 Bunionectomy Study Results

NEW YORK, July 21, 2020 -- Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today.

Yahoo | July 21, 2020

Pacira (PCRX) Provides Preliminary Results for Second Quarter

Pacira (PCRX) reports preliminary results for the second quarter of 2020. The company's product sales are hurt by the COVID-19 pandemic. The stock fell in pre-market trading.

Yahoo | July 7, 2020

Read More 'ATXI' Stories Here

ATXI Price Returns

1-mo -3.87%
3-mo -1.44%
6-mo 22.15%
1-year 87.63%
3-year 110.40%
5-year N/A
YTD 13.75%
2019 77.78%
2018 49.17%
2017 N/A
2016 N/A
2015 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.7809 seconds.